Fluphenazine decanoate bnf

The intravenous route is not FDA approved and is generally not recommended except when no other alternatives are available. Intravenous administration appears to be associated with a higher risk of QT prolongation and torsade de pointes (TdP) than other forms of administration. The manufacturer recommends ECG monitoring for QT prolongation and arrhythmias if IV administration is required. A dose in the range of 1 to 5 mg IV has been suggested, with the dose being repeated at 30 to 60 minute intervals, if needed. A maximum IV dose has not been established. The lowest effective dose should be used in conjunction with conversion to oral therapy as soon as possible.

People with schizophrenia are particularly vulnerable and need social supports — decent housing, income support, supportive friends and family, and something worthwhile to do. Most people with schizophrenia become ill at the age they would be making career choices, undergoing training and forming adult relationships. As a result, they often lack social and work skills. So in addition to medication, people with schizophrenia may need training in social skills, money management and problem-solving. Those who can work often need further training and employment support.

Fluphenazine decanoate bnf

fluphenazine decanoate bnf


fluphenazine decanoate bnffluphenazine decanoate bnffluphenazine decanoate bnffluphenazine decanoate bnffluphenazine decanoate bnf